Utilising this approach, protein quantification within tumour samples in the TCGA cohort12 via reverse phase protein array (RPPA) reveals that presumed active YAP levels are higher in patients affected with any common, canonical Hippo kinase module inactivating mutation (NF2, LATS1/2, SAV1) (Figure 2A). The gene discussed is LATS1; the disease is neoplasm.